Abstract
A significant amount of research has been focused on the relationship between hormones and Alzheimers disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimers disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimers disease. This review provides information supporting the "gonadotropin hypothesis, " puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimers disease, and discusses potential therapeutic anti-gonadotropin compounds.
Keywords: Luteinizing hormone (LH), follicle-stimulating hormone (FSH), Alzheimer's disease, gonadotropin releasing hormone (GnRH), cell cycle, estrogen
Current Pharmaceutical Design
Title: Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression
Volume: 12 Issue: 6
Author(s): Christopher W. Gregory, Craig S. Atwood, Mark A. Smith and Richard L. Bowen
Affiliation:
Keywords: Luteinizing hormone (LH), follicle-stimulating hormone (FSH), Alzheimer's disease, gonadotropin releasing hormone (GnRH), cell cycle, estrogen
Abstract: A significant amount of research has been focused on the relationship between hormones and Alzheimers disease. However, the majority of this work has been on estrogen and more recently testosterone. A serendipitous patient encounter led one of us (RLB) to question whether other hormones of the hypothalamic-pituitary-gonadal axis could be playing a role in the pathogenesis of Alzheimers disease. The age-related decline in reproductive function results in a dramatic decrease in serum estrogen and testosterone concentrations and an equally dramatic compensatory increase in serum luteinizing hormone concentrations. Indeed, there is growing evidence that the gonadotropin, luteinizing hormone, which regulates serum estrogen and testosterone concentrations, could be an important causative factor in the development of Alzheimers disease. This review provides information supporting the "gonadotropin hypothesis, " puts forth a novel mechanism of how changes in serum luteinizing hormone concentrations could contribute to the pathogenesis of Alzheimers disease, and discusses potential therapeutic anti-gonadotropin compounds.
Export Options
About this article
Cite this article as:
Gregory W. Christopher, Atwood S. Craig, Smith A. Mark and Bowen L. Richard, Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474288
DOI https://dx.doi.org/10.2174/138161206775474288 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Editorial (Thematic Issue: Chemoinformatics Models for Pharmaceutical Design, Part 2)
Current Pharmaceutical Design Design of Peptide Imaging Agents for Whole-body and Intraoperative Molecular Imaging
Current Medicinal Chemistry Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology An Overview of Computer-aided Drug Design Tools and Recent Applications in Designing of Anti-diabetic Agents
Current Drug Targets Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Protein & Peptide Letters Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry MicroRNAs in Cancer Gene Therapy: Another Look
Current Cancer Therapy Reviews Sentinel Node Imaging
Current Medical Imaging Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
Current Pharmaceutical Design The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Neurological Aspects of Grief
CNS & Neurological Disorders - Drug Targets Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma
Medicinal Chemistry Targeting Steroid Hormone Receptor Pathways in the Treatment of Hormone Dependent Cancers
Current Pharmaceutical Biotechnology Role of Islet-, Gut-, and Adipocyte-Derived Hormones in the Central Control of Food Intake and Body Weight: Implications for an Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Current Diabetes Reviews Molecular Docking Studies of the Antitumoral Activity and Characterization of New Chalcone
Current Topics in Medicinal Chemistry